Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates

Juan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, Michael Seaman, David C. Montefiori, Celia Labranche, Nicole L. Yates, Xiaoying Shen, Georgia D. Tomaras, Guido Ferrari, Kathryn E. Foulds, Adrian McDermott, Shing Fen Kao, Mario Roederer, Natalie Hawkins, Steve Self, Jiansheng Yao, Patrick Farrell, Sanjay Phogat, Jim Tartaglia & 12 others Susan W. Barnett, Brian Burke, Anthony Cristillo, Deborah Weiss, Carter Lee, Karen Kibler, Bertram Jacobs, Benedikt Asbach, Ralf Wagner, Song Ding, Giuseppe Pantaleo, Mariano Esteban

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Wecompared the HIV-1-specific cellular and humoral immune responses elicited in rhesus macaques immunized with two poxvirus vectors (NYVAC and ALVAC) expressing the same HIV-1 antigens from clade C, Env gp140 as a trimeric cell-released protein and a Gag-Pol-Nef polyprotein as Gag-induced virus-like particles (VLPs) (referred to as NYVAC-C and ALVAC-C). The immunization protocol consisted of two doses of the corresponding poxvirus vector plus two doses of a combination of the poxvirus vector and a purified HIV-1 gp120 protein from clade C. This immunogenicity profile was also compared to that elicited by vaccine regimens consisting of two doses of the ALVAC vector expressing HIV-1 antigens from clades B/E (ALVAC-vCP1521) plus two doses of a combination of ALVAC-vCP1521 and HIV-1 gp120 protein from clades B/E (similar to the RV144 trial regimen) or clade C. The results showed that immunization of macaques with NYVAC-C stimulated at different times more potent HIV-1-specific CD4+ T-cell responses and induced a trend toward higher-magnitude HIV-1-specific CD8+ T-cell immune responses than did ALVAC-C. Furthermore, NYVAC-C induced a trend toward higher levels of binding IgG antibodies against cladeCHIV-1 gp140, gp120, or murine leukemia virus (MuLV) gp70-scaffolded V1/V2 and toward best cross-clade-binding IgG responses against HIV-1 gp140 from clades A, B, and groupMconsensus, than did ALVAC-C. Of the linear binding IgG responses, most were directed against the V3 loop in all immunization groups. Additionally, NYVAC-C and ALVAC-C also induced similar levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) responses. Interestingly, binding IgA antibody levels against HIV-1 gp120 orMuLVgp70-scaffolded V1/V2 were absent or very low in all immunization groups. Overall, these results provide a comprehensive survey of the immunogenicity of NYVACversus ALVAC expressing HIV-1 antigens in nonhuman primates and indicate thatNYVACmay represent an alternative candidate to ALVAC in the development of a future HIV-1 vaccine.

Original languageEnglish (US)
Pages (from-to)8525-8539
Number of pages15
JournalJournal of Virology
Volume89
Issue number16
DOIs
StatePublished - 2015

Fingerprint

Poxviridae
env Gene Products
Human immunodeficiency virus 1
Primates
HIV-1
antigens
HIV Antigens
proteins
Immunization
immunization
Immunoglobulin G
immune response
dosage
Antibodies
antibodies
pol Gene Products
T-lymphocytes
Murine leukemia virus
T-Lymphocytes
gag Gene Products

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates. / García-Arriaza, Juan; Perdiguero, Beatriz; Heeney, Jonathan; Seaman, Michael; Montefiori, David C.; Labranche, Celia; Yates, Nicole L.; Shen, Xiaoying; Tomaras, Georgia D.; Ferrari, Guido; Foulds, Kathryn E.; McDermott, Adrian; Kao, Shing Fen; Roederer, Mario; Hawkins, Natalie; Self, Steve; Yao, Jiansheng; Farrell, Patrick; Phogat, Sanjay; Tartaglia, Jim; Barnett, Susan W.; Burke, Brian; Cristillo, Anthony; Weiss, Deborah; Lee, Carter; Kibler, Karen; Jacobs, Bertram; Asbach, Benedikt; Wagner, Ralf; Ding, Song; Pantaleo, Giuseppe; Esteban, Mariano.

In: Journal of Virology, Vol. 89, No. 16, 2015, p. 8525-8539.

Research output: Contribution to journalArticle

García-Arriaza, J, Perdiguero, B, Heeney, J, Seaman, M, Montefiori, DC, Labranche, C, Yates, NL, Shen, X, Tomaras, GD, Ferrari, G, Foulds, KE, McDermott, A, Kao, SF, Roederer, M, Hawkins, N, Self, S, Yao, J, Farrell, P, Phogat, S, Tartaglia, J, Barnett, SW, Burke, B, Cristillo, A, Weiss, D, Lee, C, Kibler, K, Jacobs, B, Asbach, B, Wagner, R, Ding, S, Pantaleo, G & Esteban, M 2015, 'Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates', Journal of Virology, vol. 89, no. 16, pp. 8525-8539. https://doi.org/10.1128/JVI.01265-15
García-Arriaza, Juan ; Perdiguero, Beatriz ; Heeney, Jonathan ; Seaman, Michael ; Montefiori, David C. ; Labranche, Celia ; Yates, Nicole L. ; Shen, Xiaoying ; Tomaras, Georgia D. ; Ferrari, Guido ; Foulds, Kathryn E. ; McDermott, Adrian ; Kao, Shing Fen ; Roederer, Mario ; Hawkins, Natalie ; Self, Steve ; Yao, Jiansheng ; Farrell, Patrick ; Phogat, Sanjay ; Tartaglia, Jim ; Barnett, Susan W. ; Burke, Brian ; Cristillo, Anthony ; Weiss, Deborah ; Lee, Carter ; Kibler, Karen ; Jacobs, Bertram ; Asbach, Benedikt ; Wagner, Ralf ; Ding, Song ; Pantaleo, Giuseppe ; Esteban, Mariano. / Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates. In: Journal of Virology. 2015 ; Vol. 89, No. 16. pp. 8525-8539.
@article{57c9e92d91dd4a468232f15b530c2d3d,
title = "Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates",
abstract = "Wecompared the HIV-1-specific cellular and humoral immune responses elicited in rhesus macaques immunized with two poxvirus vectors (NYVAC and ALVAC) expressing the same HIV-1 antigens from clade C, Env gp140 as a trimeric cell-released protein and a Gag-Pol-Nef polyprotein as Gag-induced virus-like particles (VLPs) (referred to as NYVAC-C and ALVAC-C). The immunization protocol consisted of two doses of the corresponding poxvirus vector plus two doses of a combination of the poxvirus vector and a purified HIV-1 gp120 protein from clade C. This immunogenicity profile was also compared to that elicited by vaccine regimens consisting of two doses of the ALVAC vector expressing HIV-1 antigens from clades B/E (ALVAC-vCP1521) plus two doses of a combination of ALVAC-vCP1521 and HIV-1 gp120 protein from clades B/E (similar to the RV144 trial regimen) or clade C. The results showed that immunization of macaques with NYVAC-C stimulated at different times more potent HIV-1-specific CD4+ T-cell responses and induced a trend toward higher-magnitude HIV-1-specific CD8+ T-cell immune responses than did ALVAC-C. Furthermore, NYVAC-C induced a trend toward higher levels of binding IgG antibodies against cladeCHIV-1 gp140, gp120, or murine leukemia virus (MuLV) gp70-scaffolded V1/V2 and toward best cross-clade-binding IgG responses against HIV-1 gp140 from clades A, B, and groupMconsensus, than did ALVAC-C. Of the linear binding IgG responses, most were directed against the V3 loop in all immunization groups. Additionally, NYVAC-C and ALVAC-C also induced similar levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) responses. Interestingly, binding IgA antibody levels against HIV-1 gp120 orMuLVgp70-scaffolded V1/V2 were absent or very low in all immunization groups. Overall, these results provide a comprehensive survey of the immunogenicity of NYVACversus ALVAC expressing HIV-1 antigens in nonhuman primates and indicate thatNYVACmay represent an alternative candidate to ALVAC in the development of a future HIV-1 vaccine.",
author = "Juan Garc{\'i}a-Arriaza and Beatriz Perdiguero and Jonathan Heeney and Michael Seaman and Montefiori, {David C.} and Celia Labranche and Yates, {Nicole L.} and Xiaoying Shen and Tomaras, {Georgia D.} and Guido Ferrari and Foulds, {Kathryn E.} and Adrian McDermott and Kao, {Shing Fen} and Mario Roederer and Natalie Hawkins and Steve Self and Jiansheng Yao and Patrick Farrell and Sanjay Phogat and Jim Tartaglia and Barnett, {Susan W.} and Brian Burke and Anthony Cristillo and Deborah Weiss and Carter Lee and Karen Kibler and Bertram Jacobs and Benedikt Asbach and Ralf Wagner and Song Ding and Giuseppe Pantaleo and Mariano Esteban",
year = "2015",
doi = "10.1128/JVI.01265-15",
language = "English (US)",
volume = "89",
pages = "8525--8539",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "16",

}

TY - JOUR

T1 - Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates

AU - García-Arriaza, Juan

AU - Perdiguero, Beatriz

AU - Heeney, Jonathan

AU - Seaman, Michael

AU - Montefiori, David C.

AU - Labranche, Celia

AU - Yates, Nicole L.

AU - Shen, Xiaoying

AU - Tomaras, Georgia D.

AU - Ferrari, Guido

AU - Foulds, Kathryn E.

AU - McDermott, Adrian

AU - Kao, Shing Fen

AU - Roederer, Mario

AU - Hawkins, Natalie

AU - Self, Steve

AU - Yao, Jiansheng

AU - Farrell, Patrick

AU - Phogat, Sanjay

AU - Tartaglia, Jim

AU - Barnett, Susan W.

AU - Burke, Brian

AU - Cristillo, Anthony

AU - Weiss, Deborah

AU - Lee, Carter

AU - Kibler, Karen

AU - Jacobs, Bertram

AU - Asbach, Benedikt

AU - Wagner, Ralf

AU - Ding, Song

AU - Pantaleo, Giuseppe

AU - Esteban, Mariano

PY - 2015

Y1 - 2015

N2 - Wecompared the HIV-1-specific cellular and humoral immune responses elicited in rhesus macaques immunized with two poxvirus vectors (NYVAC and ALVAC) expressing the same HIV-1 antigens from clade C, Env gp140 as a trimeric cell-released protein and a Gag-Pol-Nef polyprotein as Gag-induced virus-like particles (VLPs) (referred to as NYVAC-C and ALVAC-C). The immunization protocol consisted of two doses of the corresponding poxvirus vector plus two doses of a combination of the poxvirus vector and a purified HIV-1 gp120 protein from clade C. This immunogenicity profile was also compared to that elicited by vaccine regimens consisting of two doses of the ALVAC vector expressing HIV-1 antigens from clades B/E (ALVAC-vCP1521) plus two doses of a combination of ALVAC-vCP1521 and HIV-1 gp120 protein from clades B/E (similar to the RV144 trial regimen) or clade C. The results showed that immunization of macaques with NYVAC-C stimulated at different times more potent HIV-1-specific CD4+ T-cell responses and induced a trend toward higher-magnitude HIV-1-specific CD8+ T-cell immune responses than did ALVAC-C. Furthermore, NYVAC-C induced a trend toward higher levels of binding IgG antibodies against cladeCHIV-1 gp140, gp120, or murine leukemia virus (MuLV) gp70-scaffolded V1/V2 and toward best cross-clade-binding IgG responses against HIV-1 gp140 from clades A, B, and groupMconsensus, than did ALVAC-C. Of the linear binding IgG responses, most were directed against the V3 loop in all immunization groups. Additionally, NYVAC-C and ALVAC-C also induced similar levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) responses. Interestingly, binding IgA antibody levels against HIV-1 gp120 orMuLVgp70-scaffolded V1/V2 were absent or very low in all immunization groups. Overall, these results provide a comprehensive survey of the immunogenicity of NYVACversus ALVAC expressing HIV-1 antigens in nonhuman primates and indicate thatNYVACmay represent an alternative candidate to ALVAC in the development of a future HIV-1 vaccine.

AB - Wecompared the HIV-1-specific cellular and humoral immune responses elicited in rhesus macaques immunized with two poxvirus vectors (NYVAC and ALVAC) expressing the same HIV-1 antigens from clade C, Env gp140 as a trimeric cell-released protein and a Gag-Pol-Nef polyprotein as Gag-induced virus-like particles (VLPs) (referred to as NYVAC-C and ALVAC-C). The immunization protocol consisted of two doses of the corresponding poxvirus vector plus two doses of a combination of the poxvirus vector and a purified HIV-1 gp120 protein from clade C. This immunogenicity profile was also compared to that elicited by vaccine regimens consisting of two doses of the ALVAC vector expressing HIV-1 antigens from clades B/E (ALVAC-vCP1521) plus two doses of a combination of ALVAC-vCP1521 and HIV-1 gp120 protein from clades B/E (similar to the RV144 trial regimen) or clade C. The results showed that immunization of macaques with NYVAC-C stimulated at different times more potent HIV-1-specific CD4+ T-cell responses and induced a trend toward higher-magnitude HIV-1-specific CD8+ T-cell immune responses than did ALVAC-C. Furthermore, NYVAC-C induced a trend toward higher levels of binding IgG antibodies against cladeCHIV-1 gp140, gp120, or murine leukemia virus (MuLV) gp70-scaffolded V1/V2 and toward best cross-clade-binding IgG responses against HIV-1 gp140 from clades A, B, and groupMconsensus, than did ALVAC-C. Of the linear binding IgG responses, most were directed against the V3 loop in all immunization groups. Additionally, NYVAC-C and ALVAC-C also induced similar levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) responses. Interestingly, binding IgA antibody levels against HIV-1 gp120 orMuLVgp70-scaffolded V1/V2 were absent or very low in all immunization groups. Overall, these results provide a comprehensive survey of the immunogenicity of NYVACversus ALVAC expressing HIV-1 antigens in nonhuman primates and indicate thatNYVACmay represent an alternative candidate to ALVAC in the development of a future HIV-1 vaccine.

UR - http://www.scopus.com/inward/record.url?scp=84938152530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938152530&partnerID=8YFLogxK

U2 - 10.1128/JVI.01265-15

DO - 10.1128/JVI.01265-15

M3 - Article

VL - 89

SP - 8525

EP - 8539

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 16

ER -